SOHO-02
A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations
- Studientyp: randomisierte, multizentrische Studie
- Tumorart: Lungenkrebs
- Entität: NSCLC
-
Standort:
- Robert Bosch Krankenhaus
- E-Mail: zose@rbk.de
- Tel.: 0711 8101-7757 oder -7696
- Website
- Rekrutierungsstatus: rekrutierend
- Alter: 18+
- Studienphase: keine
- Weitere Informationen
